These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 35630702)

  • 1. Determination of Anti-Alzheimer's Disease Activity of Selected Plant Ingredients.
    Tuzimski T; Petruczynik A
    Molecules; 2022 May; 27(10):. PubMed ID: 35630702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinesterase Activity of Selected Medicinal Plants from Navarra Region of Spain and a Detailed Phytochemical Investigation of
    de Torre MP; Cavero RY; Calvo MI
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation, Characterization, and In Silico Interaction Studies of Bioactive Compounds from Caesalpinia bonducella with Target Proteins Involved in Alzheimer's Disease.
    Khoba K; Kumar S; Chatterjee S; Purty RS
    Appl Biochem Biotechnol; 2023 Apr; 195(4):2216-2234. PubMed ID: 35507252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
    Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
    Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of oxidative stress and other pathologies in Alzheimer's disease.
    Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
    Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer's Disease.
    Wang S; Kong X; Chen Z; Wang G; Zhang J; Wang J
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
    Shimohama S
    Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease.
    Sivaraman B; Raji V; Velmurugan BA; Natarajan R
    CNS Neurol Disord Drug Targets; 2022; 21(5):427-449. PubMed ID: 34602041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.
    Przybyłowska M; Dzierzbicka K; Kowalski S; Chmielewska K; Inkielewicz-Stepniak I
    Curr Neuropharmacol; 2021; 19(8):1323-1344. PubMed ID: 33342413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase.
    Ahmed S; Khan ST; Zargaham MK; Khan AU; Khan S; Hussain A; Uddin J; Khan A; Al-Harrasi A
    Biomed Pharmacother; 2021 Jul; 139():111609. PubMed ID: 33915501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer's disease.
    Orhan IE
    Curr Med Chem; 2012; 19(14):2252-61. PubMed ID: 22414107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
    Musiał A; Bajda M; Malawska B
    Curr Med Chem; 2007; 14(25):2654-79. PubMed ID: 17979717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors.
    Shah AA; Dar TA; Dar PA; Ganie SA; Kamal MA
    Curr Drug Metab; 2017; 18(2):96-111. PubMed ID: 27890007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§.
    Milelli A; De Simone A; Ticchi N; Chen HH; Betari N; Andrisano V; Tumiatti V
    Curr Med Chem; 2017; 24(32):3522-3546. PubMed ID: 28294041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylcholinesterase inhibition in Alzheimer's Disease.
    Ibach B; Haen E
    Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aqueous extract of Securidaca longipendunculata Oliv. and Olax subscropioidea inhibits key enzymes (acetylcholinesterase and butyrylcholinesterase) linked with Alzheimer's disease in vitro.
    Saliu JA; Olabiyi AA
    Pharm Biol; 2017 Dec; 55(1):252-257. PubMed ID: 27927065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.